Liver Regeneration through Autologous Bone Marrow Cell Infusion Therapy
Yamaguchi University Graduate School of Medicine - Department of Gastroenterology and Hepatology
For many liver cirrhosis cases, anti-viral therapy has enabled control and elimination of hepatitis virus, but substantial improvements in vital prognosis for decompensated liver cirrhosis have been prevented by liver fibrosis and hepatocellular carcinoma. Currently a surgical liver transplant is the only treatment for progressed decompensated liver cirrhosis but globally we are facing a serious donor shortage and transplant patients must also contend with immune rejection.
To overcome these issues, the Department of Gastroenterology and Hepatology at Yamaguchi University Graduate School of Medicine in Japan have developed liver regeneration therapies using autologous bone marrow cells for decompensated liver cirrhosis, as well as conducting clinical research of a less-invasive liver-regeneration therapy using cultured autologous bone marrow-derived MSCs. To facilitate this, they have been developing a cell processing isolator system driven by artificial intelligence for cultured autologous bone marrow-derived MSCs.
Widespread adoption of this liver regeneration therapy throughout society may be expected to lead to not only longer life for decompensated liver cirrhosis, who until now have had no recourse to curative therapies other than transplantation, but also reduced medical costs and a lighter social welfare burden.